Style | Citing Format |
---|---|
MLA | Dastan M, et al.. "Gallic Acid Ameliorates Lps-Induced Memory Decline by Modulating Nf-Κb, Tnf-Α, and Caspase 3 Gene Expression and Attenuating Oxidative Stress and Neuronal Loss in the Rat Hippocampus." Metabolic Brain Disease, vol. 40, no. 1, 2025, pp. -. |
APA | Dastan M, Rajaei Z, Sharifi M, Salehi H (2025). Gallic Acid Ameliorates Lps-Induced Memory Decline by Modulating Nf-Κb, Tnf-Α, and Caspase 3 Gene Expression and Attenuating Oxidative Stress and Neuronal Loss in the Rat Hippocampus. Metabolic Brain Disease, 40(1), -. |
Chicago | Dastan M, Rajaei Z, Sharifi M, Salehi H. "Gallic Acid Ameliorates Lps-Induced Memory Decline by Modulating Nf-Κb, Tnf-Α, and Caspase 3 Gene Expression and Attenuating Oxidative Stress and Neuronal Loss in the Rat Hippocampus." Metabolic Brain Disease 40, no. 1 (2025): -. |
Harvard | Dastan M et al. (2025) 'Gallic Acid Ameliorates Lps-Induced Memory Decline by Modulating Nf-Κb, Tnf-Α, and Caspase 3 Gene Expression and Attenuating Oxidative Stress and Neuronal Loss in the Rat Hippocampus', Metabolic Brain Disease, 40(1), pp. -. |
Vancouver | Dastan M, Rajaei Z, Sharifi M, Salehi H. Gallic Acid Ameliorates Lps-Induced Memory Decline by Modulating Nf-Κb, Tnf-Α, and Caspase 3 Gene Expression and Attenuating Oxidative Stress and Neuronal Loss in the Rat Hippocampus. Metabolic Brain Disease. 2025;40(1):-. |
BibTex | @article{ author = {Dastan M and Rajaei Z and Sharifi M and Salehi H}, title = {Gallic Acid Ameliorates Lps-Induced Memory Decline by Modulating Nf-Κb, Tnf-Α, and Caspase 3 Gene Expression and Attenuating Oxidative Stress and Neuronal Loss in the Rat Hippocampus}, journal = {Metabolic Brain Disease}, volume = {40}, number = {1}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - Dastan M AU - Rajaei Z AU - Sharifi M AU - Salehi H TI - Gallic Acid Ameliorates Lps-Induced Memory Decline by Modulating Nf-Κb, Tnf-Α, and Caspase 3 Gene Expression and Attenuating Oxidative Stress and Neuronal Loss in the Rat Hippocampus JO - Metabolic Brain Disease VL - 40 IS - 1 SP - EP - PY - 2025 ER - |